Pfizer (XSWX:PFE) Other Income (Expense): CHF-8,484 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:PFE Pfizer Inc XSWX:PFE
59 GF Score
Price CHF22.56
GF Value CHF21.50
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Pfizer Other Income (Expense)?

Pfizer XSWX:PFE -1.76% 59 Other Income (Expense) is CHF-8,484 Mil as of Jun. 2026. GuruFocus rates XSWX:PFE with a GF Score™ of 59/100 and a GF Value™ of CHF21.50 (Fairly Valued). The stock has 8 warning signs investors should review.

Pfizer's other income expense for the Pfizer's pretax income for the three months ended in Jun. 2026 was CHF-2,906 Mil. Its other income expense for the trailing twelve months (TTM) ended in Jun. 2026 was CHF-8,484 Mil.

Pfizer  (XSWX:PFE) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Pfizer Other Income (Expense) Historical Data

* Premium members only.

The historical data trend for Pfizer's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfizer Other Income (Expense) Chart

Pfizer Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,714.90 -2,236.77 -2,398.96 -3,895.40 -6,230.96

Pfizer Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -182.97 -1,336.65 -3,812.37 -429.08 -2,906.26
XSWX:PFE
59GF Score
Pfizer Inc XSWX:PFE
Other Income (Expense) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pfizer Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-8,484 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Income (Expense) →
What does a Other Income (Expense) of CHF-8,484 Mil mean?
Pfizer (XSWX:PFE) has a Other Income (Expense) of CHF-8,484 Mil as of Jun. 2026. Other income and expenses that a company records on the income statement. View historical data on Pfizer and its competitors.
Is Pfizer's Other Income (Expense) too high?
Pfizer's current Other Income (Expense) is CHF-8,484 Mil. Overall, Pfizer has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pfizer's Other Income (Expense) compare to GILD and BMY?
Pfizer's Other Income (Expense) of CHF-8,484 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Income (Expense) for a Drug Manufacturers company?
A good Other Income (Expense) depends on the Drug Manufacturers industry context. However, Other Income (Expense) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Income (Expense) mean?
A high Other Income (Expense) can signal that a stock is expensive relative to its fundamentals. Other income and expenses that a company records on the income statement. View historical data on Pfizer and its competitors. Pfizer's current Other Income (Expense) is CHF-8,484 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pfizer stock overvalued right now?
Based on GuruFocus' analysis, Pfizer (XSWX:PFE) is currently considered Fairly Valued. The stock's GF Value™ is CHF21.50, compared to a current price of CHF22.56 — trading 4.9% above its estimated fair value. The current Other Income (Expense) is CHF-8,484 Mil. Pfizer's overall GF Score™ is 59/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Income (Expense) calculated?
Other Income (Expense) is calculated from a company's financial statements. For Pfizer (XSWX:PFE), the current Other Income (Expense) is CHF-8,484 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pfizer (XSWX:PFE) Overvalued in 2026?

Based on GuruFocus' analysis, Pfizer stock appears to be overvalued. The current stock price of CHF22.56 is trading 4.9% above its estimated GF Value™ of CHF21.50. GuruFocus considers Pfizer to be Fairly Valued.

Key valuation signals for XSWX:PFE:

  • Other Income (Expense): CHF-8,484 Mil
  • GF Value™: CHF21.50 vs. price of CHF22.56 (4.9% above fair value)
  • GF Score™: 59/100 with 8 warning signs

No single metric tells the full story. See the XSWX:PFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pfizer Business Description

Address 66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
59GF Score

Get the complete analysis for XSWX:PFE

Other Income (Expense) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF22.56
Price
CHF21.50
GF Value